Affordable Access

deepdyve-link
Publisher Website

Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature.

Authors
  • Fan, Siyuan1
  • Ren, Haitao1
  • Zhao, Luo2
  • Yin, Jian3
  • Feng, Guodong4
  • Wang, Jiawei5
  • Guan, Hongzhi1
  • 1 Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. , (China)
  • 2 Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. , (China)
  • 3 Department of Neurology, Beijing Hospital, Beijing, China. , (China)
  • 4 Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai, China. , (China)
  • 5 Department of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. , (China)
Type
Published Article
Journal
Asia-Pacific journal of clinical oncology
Publication Date
Dec 01, 2020
Volume
16
Issue
6
Pages
291–298
Identifiers
DOI: 10.1111/ajco.13375
PMID: 32893999
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Immune checkpoint inhibitors (ICIs) have made a breakthrough in cancer therapy. Patients treated with ICIs may develop immune-related adverse events (irAEs) due to the upregulated activity of the immune system. With the increasing use of ICIs, irAEs are more frequently reported and have become important challenges in many patients. Neurological irAEs, which include encephalitis, myelitis, aseptic meningitis, peripheral neuropathy, myasthenia gravis, and myositis, consist of a distinct group of neuroinflammatory disorders. These disorders are rare but frequently severe with high mortality and morbidity. Patients with neurological irAEs are generally responsive to immune-modulating therapy. Therefore, early recognition and treatment are the most important ways to improve their prognosis. Here, we provide a comprehensive review of neurological irAEs associated with ICIs and focus on these affecting central nervous systems. © 2020 John Wiley & Sons Australia, Ltd.

Report this publication

Statistics

Seen <100 times